Cargando...
BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells
BRAF(V600E) is the most frequent oncogenic mutation identified in papillary thyroid cancer (PTC). In PTC patients who do not respond to standard treatment, BRAF inhibitors are currently tested as alternative strategies. However, as observed for other targeted therapies, patients eventually develop d...
Gardado en:
| Publicado en: | Int J Mol Sci |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
MDPI
2021
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8198461/ https://ncbi.nlm.nih.gov/pubmed/34072194 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms22115744 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|